Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
441
datasets available to search
ShareScore release 0.9.0
Dataset results
441 results for “Amyloidosis”
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
ClinicalTrials.gov study NCT01659658. IPD Sharing: YES. Countries: 15. Publications: 2.
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
ClinicalTrials.gov study NCT04504825. IPD Sharing: YES. Countries: 19. Publications: 0.
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
ClinicalTrials.gov study NCT04512235. IPD Sharing: YES. Countries: 19. Publications: 0.
Assessment of the association of new biomarkers (GDF15, ST2, galectin-3, TIMP-1, MMP-9, NfL) and plasma prothrombotic potential in the course of cardiac transthyretin amyloidosis.
<p><span>The development of cardiac amyloidosis (ATTR) is caused by the deposition of misfolded, insoluble proteins in the extracellular matrix of tissues. An important element of the clinical presentation of the disease is the increased risk of thromboembolic complications. Currently, there is limited published data on the potential role of new heart failure biomarkers in the assessment of ATTR cardiomyopathy, particularly in the assessment of asymptomatic carriers of pathogenic transthyretin (TTR) variants.</span></p> <p><span>Purpose of the study: To assess the diagnostic value of biomarkers related to heart failure (growth differentiation factor-15 (GDF15), soluble suppression of tumorigenicity-2 (ST2), galectin-3), amyloidosis ( retinol binding protein 4 (RBP4, transthyretin) , tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix metalloproteinase-9 (MMP-9, matrix metalloproteinase-9), neurofilament light chain (NfL)) and the generation potential thrombin as a marker of the prothrombotic state in the course of ATTR.</span></p> <p><span>Methods: This prospective, single-center study included consecutive patients diagnosed with ATTR, asymptomatic carriers of pathogenic TTR variants, and a matched control group of healthy volunteers. The values of these biomarkers were evaluated using the ELISA method from peripheral blood (enzyme-linked immunosorbent assay) GDF15, ST2, RBP4 (TTR), TIMP-1, MMP-9, galectin-3, NfL. Additionally, the prothrombotic potential of plasma was tested using the calibrated automatic thrombogram (CAT) method. Results are presented in Table 1. </span><span>The demographic and clinical characteristics of the study population are presented in Table 2 and Table 3.</span></p> <p><span>Conclusions: The project provides information on the value of novel biomarkers in the assessment of ATTR cardiomyopathy, especially in the assessment of asymptomatic carriers of pathogenic TTR variants. Moreover, it evaluated prothrombotic state in the course of ATTR.</span></p>
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
ClinicalTrials.gov study NCT00890552. IPD Sharing: NO. Countries: 1. Publications: 2.
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
ClinicalTrials.gov study NCT03499808. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
ClinicalTrials.gov study NCT01683825. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
ClinicalTrials.gov study NCT04973137. IPD Sharing: NO. Countries: 23. Publications: 1.
Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant
ClinicalTrials.gov study NCT03862807. IPD Sharing: YES. Countries: 7. Publications: 3.
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
ClinicalTrials.gov study NCT01961921. IPD Sharing: YES. Countries: 7. Publications: 1.
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
ClinicalTrials.gov study NCT01222260. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis
ClinicalTrials.gov study NCT05139680. IPD Sharing: NO. Countries: 1. Publications: 1.
Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations
ClinicalTrials.gov study NCT03812172. IPD Sharing: UNDECIDED. Countries: 1. Publications: 10.
Transthyretin Amyloidosis Outcome Survey (THAOS)
ClinicalTrials.gov study NCT00628745. IPD Sharing: NO. Countries: 25. Publications: 26.
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
ClinicalTrials.gov study NCT01318902. IPD Sharing: YES. Countries: 5. Publications: 1.
Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
ClinicalTrials.gov study NCT01617967. IPD Sharing: YES. Countries: 7. Publications: 1.
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
ClinicalTrials.gov study NCT01960348. IPD Sharing: YES. Countries: 21. Publications: 7.
The Effect of Diflunisal on Familial Amyloidosis
ClinicalTrials.gov study NCT00294671. IPD Sharing: NO. Countries: 5. Publications: 1.
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
ClinicalTrials.gov study NCT02510261. IPD Sharing: NO. Countries: 21. Publications: 3.
Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's
ClinicalTrials.gov study NCT02769000. IPD Sharing: YES. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.